CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
cycloastragenol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02530255
NCT02530255N/ACompleted
CompareCT.gov

Evaluation of an Oral Telomerase Activator on Retinal Amyloid

Chippewa Valley Eye Clinic·interventional·Posted Aug 21, 2015·Updated Jul 5, 2019

In Brief

A clinical study evaluating cycloastragenol and placebo (for cycloastragenol) for Alzheimer Disease. Completed, enrolled 48 participants across 1 site.

Detailed Summary

A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease. Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsTA-Sciences

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 21, 2015
Enrollment StartDec 1, 2016
Primary CompletionOct 31, 2018
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.9 years ago

Interventions

cycloastragenoldietary

Oral telomerase activator - cycloastragenol.

placebo (for cycloastragenol)dietary

placebo comparator, placebo for cycloastragenol.